DEXMEDETOMIDINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dexmedetomidine, and what generic alternatives are available?
Dexmedetomidine is a drug marketed by Accord Hlthcare, Actavis Inc, Am Regent, Amneal, Amneal Pharms Co, Baxter Hlthcare Corp, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland, Hengrui Pharma, Hikma, Knack, Meitheal, Milla Pharms, Mylan Institutional, Mylan Labs Ltd, Ph Health, Piramal Critical, Rising, Tagi, Teva Pharms Usa, Wilshire Pharms Inc, Zydus Pharms, Hq Spclt Pharma, and Somerset. and is included in thirty-three NDAs. There are two patents protecting this drug.
The generic ingredient in DEXMEDETOMIDINE is dexmedetomidine hydrochloride. There are fourteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the dexmedetomidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dexmedetomidine
A generic version of DEXMEDETOMIDINE was approved as dexmedetomidine hydrochloride by MYLAN INSTITUTIONAL on August 18th, 2014.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DEXMEDETOMIDINE?
- What are the global sales for DEXMEDETOMIDINE?
- What is Average Wholesale Price for DEXMEDETOMIDINE?
Summary for DEXMEDETOMIDINE
| US Patents: | 0 |
| Applicants: | 27 |
| NDAs: | 33 |
| Drug Prices: | Drug price information for DEXMEDETOMIDINE |
| What excipients (inactive ingredients) are in DEXMEDETOMIDINE? | DEXMEDETOMIDINE excipients list |
| DailyMed Link: | DEXMEDETOMIDINE at DailyMed |
Recent Clinical Trials for DEXMEDETOMIDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Istinye University | NA |
| University of Missouri-Columbia | PHASE4 |
| Sun Fei | NA |
